Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.

MLA

Kirchberg, Janine, et al. “Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.” Clinical Lymphoma, Myeloma & Leukemia, vol. 24, no. 9, Sept. 2024, pp. e277–82. EBSCOhost, https://doi.org/10.1016/j.clml.2024.05.006.

APA

Kirchberg, J., Fischer, L., Born, P., Brunner, F., Morgner, C., Fürst, D., Heyn, S., Bach, E., Brueckner, M., Jentzsch, M., Wang, S.-Y., Böttcher, S., Franke, G.-N., Schrezenmeier, H., Platzbecker, U., Merz, M., & Vučinić, V. (2024). Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia, 24(9), e277–e282. https://doi.org/10.1016/j.clml.2024.05.006

Chicago

Kirchberg, Janine, Luise Fischer, Patrick Born, Franziska Brunner, Charlotte Morgner, Daniel Fürst, Simone Heyn, et al. 2024. “Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.” Clinical Lymphoma, Myeloma & Leukemia 24 (9): e277–82. doi:10.1016/j.clml.2024.05.006.